That is very vague. It could be Q1 in 2026.
The trading update in November 2023 stated we had a cash runway to Q2 2025.
By the beginning of June 2024 we had a cash call for 8.5 million and possible 2,000,000 to shareholders of which only half of a million was raised.
This was done as a 16.7% discount to the prevailing price, and 10 to 12 months before the cash runway was supposed to expire.
Think on that one. |
Cash runway till 2026 bone-idle. |
 waterloo01 - you may be right, personally I hope not but time will tell. UK Small Cap success stories are indeed historically speaking, a bit thin on the ground & by that I mean those that develop within the UK & continue to grow.
There are plenty of signs that Angle are forging strong relationships as perhaps can be illustrated here :
'Complementary insights: Exploring the dual analysis of circulating tumour cells and circulating DNA' EACR-Illumina webinar
Thursday 06 February 2025 | 17:00 – 18:00 CET
This public webinar is hosted in collaboration with Illumina, one of our valued EACR Industry Partners. In this webinar, Anne-Sophie Pailhes-Jimenez will present dual analysis data from samples taken from lung cancer patients and she will discuss how dual analysis of liquid biopsy analytes may hold potential to capture a more comprehensive picture of tumour heterogeneity and ultimately inform personalised cancer care.
Click here to register (open to all, you do not need to be an EACR member to attend)."
Anne-Sophie Pailhes-Jimenez |
Someone, ie Illumina or Quigen or AZ will make them an offer. Long thought it... |
Decent volume today. Primarily on the back of the latest rns.
More to come and I suspect it'll continue to be a combination of new or extended contracts as well as trial results.
Interesting times that's for sure. |
Bones....maybe lauch another aliasIdea...bone idle. |
Lovely bowl chart forming over the 1 year So far we have these figures for the share price:Up 22% in 7 daysUp 40% on the monthUp 81% over 3 months |
Don't mind bones
He's still short
The next contract should be enough to squeeze him out at a hefty loss
sent from my iPhone |
Remember when adw sold all his shares thinking he was clever
Then we had PATT bones and all the other cronies talking the company down
What happened next? We saw 25p very quickly
History repeating
sent from my iPhone |
Cash runway to 2026. What are you on about bones?? |
Oh dear Bones. Been calling this a sell somce 7.5p. I would rather go by what the Co says, and its announcements through RNS rather than listen to someone like you, an anonymous poster on a bulletin board, clearly with axe to grind or trader sowing FUD.Imagine bones posting at 20 or 30p.Zero credibility |
Bone idle shows. What a plank. Use your other aliases too. #whataplank |
One is coming unless they can get an upfront payment form one of these deals soon . Yesterday's rns showed the cash position and they will want to avoid a going concern statement in the June results which will only be possible with more cash on the books . The broker note didn't show a huge uotick in likely revenues either so that's not going to do it leaving a fund raise highly probable in the next 2-4 months imo |
PATT, I disagree with your post, “Looks to me like they are trying to stimulate buying to get an equity raise done.” The trial results were just released, and it’s entirely reasonable for AN to highlight the pivotal role Parsortix played in this significant clinical trial.
This study was previously recognized by Nature Medicine as one of the 11 clinical trials poised to shape medicine in 2023. It’s a groundbreaking trial and warrants the attention it’s receiving. |
super - thanks for that and well spotted.
Nicola Aceto is one of the leading experts in the field and his lab has been set up purely to research and study circulating tumour cells to understand the metastatic process and develop therapies to prevent it. Research on CTCs is what they do and it's really encouraging that he has chosen the Parsortix system to install in his lab and for this research. The link below is to a short video and although it's old it's worth a look for any who may not be familiar with his work. |
we anticipate that the Parsortix system will be a crucial component for the development of drugs targeting the metastatic cascade..... Alongside our ongoing collaboration with ETH Zurich, we look forward to working with PAGE Therapeutics to support their development drugs targeting metastatic spread."Fantastic newsWell done Angle Team. Another breakthrough research paper....momentum building |
I do talk 'drivel' - post #22949 |
(Sharecast News) - Liquid biopsy specialist Angle announced on Friday that its Parsortix system played a pivotal role in groundbreaking breast cancer research published in Nature Medicine by a team led by professor Nicola Aceto at ETH Zurich. |
Bermuda - I see that Page Therapeutics has Meret Gaugler on the board. She was appointed as 'Partner-at-Large in the Growth Investments team of Novo Holdings' in the middle of last year, so if he produces any decent human results he won't be short of friends with deep pockets to help. As you say - worth keeping an eye on. |
there may very well be a pharmaceutical co more advanced in the clinical trials arena that may implement Angle technology and with positive results then Fastrack Designation will be achieved to eradicate cancer. Well done the angle team.....🐭 |
Tight lines...love it.Ps I'm a buyer (watch Game stop film) |
A little competition for your services is never a bad thing. There are no 'barriers to entry' as such but the patents and of course FDA approval is a big lure.
Tight lines! |
An online article published only this morning in the top journal on the planet illustrating the fundamental part Parsortix has played in facilitating a whole new approach to cancer treatment. PR gold & Newland is quite rightly proud of his team. |
"“Parsortix system is the ONLY liquid Biopsy solution with FDA product clearance for harvesting intact cancer cells from patient blood for analysis.”
Is that statement actually true ? FDA approval for Parsortix seems to be an anomaly rather than a recomendation.
There are various alternative systems. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
